NASDAQ: IRD · Life Sciences · 10 alerts · CIK 1228627
Share price
$4.04Close, Nov 16
Market cap
$390M
Shares outstanding
96.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Opus Genetics, Inc. filings on SEC EDGAR ↗
Opus Genetics CEO George Magrath Sells $110K of Stock
George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).
Opus Genetics COO Joseph K. Schachle Sells $17K of Stock
Joseph K. Schachle, COO, sold 4,767 shares of Opus Genetics, Inc. at $3.56 a share, worth $17K in total on Oct 23, 2026. Shares held after the trade: 286,673 (-1.6%).
Opus Genetics President Benjamin R. Yerxa Sells $117K of Stock
Benjamin R. Yerxa, President, sold 33,189 shares of Opus Genetics, Inc. at $3.53 to $3.55 a share (average $3.54) in 2 transactions, worth $117K in total on Oct 23, 2026. Shares held after the trade: 670,917 (-3.7%).
Opus Genetics CFO Robert E. Gagnon Sells $49.6K of Stock
Robert E. Gagnon, CFO, sold 14,000 shares of Opus Genetics, Inc. at $3.55 a share, worth $49.6K in total on Oct 23, 2026. Shares held after the trade: 542,375 (-2.5%).
Opus Genetics CEO George Magrath Sells $34.4K of Stock
George Magrath, CEO, sold 9,591 shares of Opus Genetics, Inc. at $3.58 a share, worth $34.4K in total on Oct 23, 2026. Shares held after the trade: 2,038,894 (-0.5%).
Opus Genetics Insider Foundation Fighting Blindness Retinal Degeneration Fund Sells $2.76M of Stock
Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. at $4.96 a share, worth $2.76M in total on Sep 30, 2026. Shares held after the trade: 3,236,171 (-14.7%).